Clinical trials: QTc Interval
Advanced Solid Tumor
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
- Trial name
- NCT04887194
- Testing
- Sitravatinib, Warfarin, Dextromethorphan
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mirati Therapeutics Inc.
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
The primary objective of this study is to assess lofexidine related effects on QTc (an interval of the heart rhythm) in subjects receiving buprenorphine maintenance.
- Trial name
- NCT01820442
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Cancer
A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
This is a Phase I, multicenter, 2-part study with Part 1 designed as a safety lead-in and Part 2 designed to evaluate the effect of GSK2118436 on cardiac repolarization (corrected QT interval [QTc] duration) as compared with…
- Trial name
- NCT01738451
- Testing
- GSK2118436 75 mg
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Healthy
A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
This Phase I study will be performed in a double-blind, randomized, crossover design in healthy male and female subjects. The central ECG laboratory will be blinded to treatment.
- Trial name
- NCT01416259
- Testing
- Withdraw treatment
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Heron Therapeutics
Smoking Cessation
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
- Trial name
- NCT05566288
- Testing
- Cytisinicline, Moxifloxacin
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
QT/QTc
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
- Trial name
- NCT05841160
- Testing
- Ecopipam Hydrochloride, Moxifloxacin
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Healthy Volunteers
A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics
A randomized, single-center, placebo and positive control, 4-period and 4-crossover clinical study with the following main purposes: (1) To evaluate the effect of a single-dose oral administration of nemonoxacin malate capsule on…
- Trial name
- NCT03362853
- Testing
- Nemonoxacin 500Mg Capsule, Moxifloxacin 400Mg Tablet, Nemonoxacin 750Mg Capsule
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Hypertension, Mineralocorticoid Receptor Antagonist
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
This study will test if a study drug (CS-3150) will affect the heart rate in healthy males and females. Two doses of the study drug will be tested. Heart rate is not expected to be different between the study groups.
- Trial name
- NCT04019652
- Testing
- CS-3150, Moxifloxacin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Diabetes, Healthy
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.
- Trial name
- NCT02064348
- Testing
- semaglutide, moxifloxacin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often.
- Trial name
- NCT07305831
- Testing
- Ulonivirine, Moxifloxacin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
CP-690,550 Thorough QTc Study
ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development.
- Trial name
- NCT01743677
- Testing
- CP-690,550, Moxifloxacin
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.
- Trial name
- NCT01941511
- Testing
- Rivipansel
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Healthy Volunteers
A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart
This is a randomised, double blind placebo controlled Phase I study which will assess the safety, tolerability and PK of Cortexolone 17α-propionate (and its metabolites), and its effects on the QTc interval when administered as…
- Trial name
- NCT03665194
- Testing
- Cortexolone 17α-propionate solution
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cassiopea SpA
Healthy
Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
According to the ICH Guidance Document E14, all non-antiarrhythmic drugs should be evaluated for their ability to prolong the QT interval which represents the duration of ventricular depolarization and subsequent repolarization.
- Trial name
- NCT01552928
- Testing
- Anagrelide 0.5 mg, Anagrelide 2.5 mg, Moxifloxacin
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteer
Definitive QT Study With MT-8554
This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects
- Trial name
- MT-8554 DQT (NCT03471130)
- Testing
- MT-8554 Low dose, MT-8554 High dose
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Healthy
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers
This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One will be used to identify a safe supratherapeutic dose to be used in the TQT study (Phase Two).
- Trial name
- NCT03564158
- Testing
- meropenem-vaborbactam, Moxifloxacin
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Healthy
Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers
Study to investigate the effect of BI 1744 CL on the QT/QTc interval of the ECG (electrocardiogram) in comparison to placebo
- Trial name
- NCT02172144
- Testing
- BI 1744 CL solution for inhalation, Moxifloxacin (Avalox®)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
QTc Interval
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
- Trial name
- NCT01327066
- Testing
- Droxidopa, Moxifloxacin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chelsea Therapeutics
Infections, Bacterial
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
GSK945237 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK945237 has demonstrated in vitro and in vivo activity against Gram positive [including methicillin resistant Staphylococcus aureus…
- Trial name
- NCT01039610
- Testing
- GSK945237, Linezolid, Moxifloxacin
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline